PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today reported that final results from the REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ in Italy are scheduled to be presented at 11:57 a.m. CT on Monday, April 4, 2011, at the American College of Cardiology's (ACC) 60th Annual Scientific Session & Expo in New Orleans, Louisiana. Additionally, PLC will be demonstrating RenalGuard at its booth (#3932) at the conference.

Dr. Carlo Briguori, MD, PhD, Chief, Laboratory of Interventional Cardiology, Clinica Mediterranea, Naples, Italy, and Co-Director of Clinical Research, Laboratory of Interventional Cardiology, San Raffaele Hospital, Milan, Italy, the principal investigator for the REMEDIAL II trial, will present the results during a Late Breaking Clinical Trial session at the conference.

The REMEDIAL II trial is a randomized multi-center clinical trial in Italy designed to provide an assessment of the potential benefits of induced diuresis with automated matched hydration therapy utilizing RenalGuard, compared to a control group, in reducing the incidence of Contrast Induced Nephropathy (CIN) in patients with baseline impairment in renal function undergoing cardiac catheterization procedures and percutaneous coronary interventions.